Source: Fox News
Summary
A recent study funded by the National Institutes of Health evaluated a blood test measuring levels of p-tau217, a protein that accumulates in the brain during Alzheimer’s disease. The test was found to predict the age of symptom onset with a median absolute error of about three to four years. However, the findings need to be validated in broader and more diverse populations, and the test’s predictive accuracy may not yet be sufficient for individual clinical use.
Our Reading
The advice sounds familiar.
The search for a reliable Alzheimer’s blood test continues, with new studies and tests emerging. However, concerns about accuracy and reliability remain. The Alzheimer’s Association recommends using blood tests primarily in specialized care settings for patients with cognitive impairment. Diagnosing Alzheimer’s is a multi-step process involving several types of tests, and blood testing can be an important piece of the diagnostic process. The risk of false positives and varying accuracy among tests underscores the importance of careful analysis and clinical follow-up.
It’s a familiar cycle: a new test emerges, promising early detection and prevention, but its limitations and potential drawbacks soon come to light.
Author: Evan Null
